LORFF- DO NOT KNOW WHAT IT MEANS BUT I BOUGHT
PLUS I SAID LAST NIGHT TO WATCH BNTI..
(COMTEX) B: LORUS THERAPEUTICS INC - FDA Approval To Begin Clinical T
B: LORUS THERAPEUTICS INC - FDA Approval To Begin Clinical Trials Of
Anti-Cancer Drug GTI 2040
Toronto, Ontario, Dec. 07, 1999 (Market News Publishing via COMTEX)
-- Lorus Therapeutics Inc. ("Lorus") announced that the U.S. Food and
Drug Administration ("FDA") has approved the Company's Investigational
New Drug ("IND") application to begin clinical trials of the
anti-cancer drug, GTI 2040. The clinical trial will take place under
the direction of Dr. Richard Schilsky of the Chicago Cancer Research
Center.
"The primary goal of this Phase I/II clinical trial is to look at the
safety of GTI 2040 in patients with a variety of tumors," said Mr.
Philippe G. Lacaille, chairman and chief executive officer at Lorus.
"The clinical trial of GTI 2040 is the first involving our antisense
compounds and we are very pleased to be starting it so quickly after
our recent acquisition of GeneSense Technologies. The trial will be a
dose escalating study to determine optimum dosing levels and will
involve approximately 20 to 25 patients who are non-responsive to other
therapies."
Although the primary goal of the clinical trial is to evaluate safety,
tests aimed at monitoring potential efficacy of GTI 2040 will also be
(COMTEX) B: LORUS THERAPEUTICS INC - FDA Approval To Begin Clinical T
B: LORUS THERAPEUTICS INC - FDA Approval To Begin Clinical Trials Of
Anti-Cancer Drug GTI 2040
Toronto, Ontario, Dec. 07, 1999 (Market News Publishing via COMTEX)
-- Lorus Therapeutics Inc. ("Lorus") announced that the U.S. Food and
Drug Administration ("FDA") has approved the Company's Investigational
New Drug ("IND") application to begin clinical trials of the
anti-cancer drug, GTI 2040. The clinical trial will take place under
the direction of Dr. Richard Schilsky of the Chicago Cancer Research
Center.
"The primary goal of this Phase I/II clinical trial is to look at the
safety of GTI 2040 in patients with a variety of tumors," said Mr.
Philippe G. Lacaille, chairman and chief executive officer at Lorus.
"The clinical trial of GTI 2040 is the first involving our antisense
compounds and we are very pleased to be starting it so quickly after
our recent acquisition of GeneSense Technologies. The trial will be a
dose escalating study to determine optimum dosing levels and will
involve approximately 20 to 25 patients who are non-responsive to other
therapies."
Although the primary goal of the clinical trial is to evaluate safety,
tests aimed at monitoring potential efficacy of GTI 2040 will also be
performed.
In an earlier announcement, Lorus reported that GTI 2040 had
demonstrated excellent anti-tumor activity in in vivo models when
tested against a wide variety of human tumors.
"Depending on the tumor model, we saw significant inhibition of tumor
growth, disease stabilization and in some cases, dramatic tumor
regression," said Dr. Jim Wright, president and chief scientific
officer at Lorus. "GTI 2040 was tested extensively for safety in
several animal models, and we expect to find similar safety
characteristics in our clinical trials."
Lorus is a biopharmaceutical company focused on the development of
cancer therapies. Lorus' goal is to capitalize on its pre-clinical,
clinical and regulatory expertise by developing new drug candidates
that can be used, either alone, or in combination, to successfully
manage cancer. Through an active acquisition and in-licensing program,
Lorus is building a portfolio of promising anti-cancer drugs. Late
stage clinical development and marketing will be done in cooperation
with strategic pharmaceutical partners. Founded in 1986, Lorus
Therapeutics Inc. is a public company listed on the Toronto Stock
Exchange and the Montreal Stock Exchange under the symbol LOR and on
the OTC BB exchange under the symbol LORFF.
Except for historical information, this press release contains
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risks and uncertainties, which may cause actual results to
differ materially from those statements. Those risks and uncertainties
include, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the establishment
of corporate alliances, the impact of competitive products and pricing,
new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual reports and 20-F filings.
-0-
TEL: (905) 305-1100 x234 Philippe G. Lacaille, Chairman and
TEL: (905) 305-1100 x234 Philippe G. Lacaille, Chairman an
FAX: (905) 305-1584 CEO, Lorus Therapeutics Inc.
EMAIL: info@lorusthera.com
INET: www.lorusthera.com
______________________________
(c) Corporate Dissemination Services Inc. All rights reserved.
Tel:(604) 689-1101 Fax:(604) 689-1106
RapidFAX (tm) - To get the NEWS as it happens, call (604)
689-3041.
*** end of story ***
*** end of story *** |
